中文别名2-羟基-3-甲酰胺基-5-氟吡嗪; 6-氟-3,4-二氢-3-氧代-吡嗪羧酰胺;

英文别名

T 705 (pharmaceutical); Favipiravir; Pyrazinecarboxamide,6-fluoro-3,4-dihydro-3-oxo- (9CI); 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide; CF0036; T 705|259793-96-9|T-705|T705; favipiravir-t-705; RW3035; AOB2076; UNII-EW5GL2X7E0; STL557913; HY-14768; T705; CS-0612; RP22092; AK-67681; Favipiravir (JAN/USAN/INN); Avigan (TN); AC-28900; CHEBI:134722; MFCD12032148; Favipiravir (T-705); API0008132; T 705; Favipiravir [USAN:INN:JAN]; BBL104098; ST1120855; SCHEMBL587913; D09537; ZINC13915654; J-518718; A25520; BCPP000056; EX-A2285; CTK8C4699; ZCGNOVWYSGBHAU-UHFFFAOYSA-N; 6-FLUORO-3-HYDROXYPYRAZINE-2-CARBOXAMIDE; T-705; avigan; BR-67681; FCH1143534; FT-0701282; ANW-72832; 259793-96-9; AMPZ0004; T 705,CAS; 6-fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide; SCHEMBL15157866; 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide; 6-fluoro-3-hydroxy-pyrazine-2-carboxamide; FT-0686297; AKOS005166863; PB25591; 793P969; ZINC584639713; ZINC584639712; SC-43861; 6-fluoro-3-oxo-4H-pyrazine-2-carboxamide; s7975; 6-Fluoro-3,4-dihydro-3-oxo-2-pyrazinecarboxamide; AM20080851; DB12466; S-7880; AN-1700; AKOS015995178; EW5GL2X7E0; QC-771; BCP02422; Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo-; 2-Pyrazinecarboxamide, 6-fluoro-3-hydroxy-; AC1LAOUM; CHEMBL221722; ACN-041491;